Abstract: Epoxyeicosatrienoic acids (EETs) are products of cytocrome P450 epoxygenases that have vasodilatory properties similar to endotheilum-derived hyperpolarizing factor (EDHF). The cytochrome P450 isoform CYP2J2 was cloned and identified as a source of EETs in human endothelial cells. Physiological concentrations of EETs or overexpression of CYP2J2 decreased cytolcine-induced endothelial cell adhesion molecule expression and prevented subsequent leukocyte adhesion to the vascular wall by a mechanism involving inhibition of transcription factor NF-?B and I?B kinase (IKK). The inhibitory effects of EETs were independent of their membrane hyporpolarizing effects suggesting that these molecules play an important non-vasodilatory role in vascular inflammation.
Type:
Grant
Filed:
August 9, 2000
Date of Patent:
July 12, 2005
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: This invention is directed towards a ready-to-use aqueous composition of ifosfamide. In one embodiment, the invention is directed to an aqueous ifosfamide composition which comprises ifosfamide, a pharmaceutically acceptable buffer, and water. The concentration of ifosfamide in the composition may be between about 40 mM and about 400 mM. The concentration of buffer in the composition may be between about 10 mM and about 260 mM. The molar ratio of ifosfamide to buffer may be between about 0.5:1 to about 20:1. The pH of the composition may be between about 4 and about 8.
Abstract: Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.
Type:
Grant
Filed:
September 29, 2000
Date of Patent:
May 31, 2005
Assignee:
UAF Technologies and Research, LLC
Inventors:
Joseph K. Agyin, James C. Quada, Jr., James Berger Camden
Abstract: The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC, and a retroviral protease inhibitor.
Type:
Grant
Filed:
May 28, 1999
Date of Patent:
April 5, 2005
Inventors:
Ben M. Dunn, Janet K. Yamamoto, Maki Arai
Abstract: Improved daily ration mammal feeds are provided which include minor amounts of heartworm preventative drugs, ensure that a mammal consuming the feed receives quantities of drug sufficient to establish and maintain substantially constant concentrations of the drug in the pet's bloodstream. The feeds may be produced by extrusion with addition of minor quantities of heartworm preventative drug so as to uniformly distribute the drug throughout the extruded product. Ivermectin levels of from about 2-1500 ?g/kg of extruded feed are preferred.
Type:
Grant
Filed:
October 5, 2001
Date of Patent:
March 15, 2005
Assignee:
Rubicon Scientific
Inventors:
Gordon R. Huber, David R. Jones, John C. Kuenzi, Kevin D. Kuenzi, Francisco A. Cabrera
Abstract: Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.
Type:
Grant
Filed:
September 29, 2000
Date of Patent:
March 8, 2005
Assignee:
UAF Technologies and Research, LLC
Inventors:
James Berger Camden, James Clarence Quada, Jr., Joseph K. Agyin
Abstract: Methods for treating and/or protecting H. pylori infection are described. The methods utilize non-mucosal administration of an effective amount of one or more H. pylori antigens.
Abstract: Light emitting compounds of the formula:
wherein R1 is a light-emitting moiety and R2 is a VIP-based peptide, fragment, derivative or analog thereof, said peptide being linked at an amino acid position to (C—X), wherein (C—X) is selected from the group consisting of C═O, C═S, CH(OH), C═C═O, C═NH, CH2, CH(OR), CH(NR), CH(R), CR3R4, and C(OR3)OR4 where R, R3, and R4 are alkyl moieties or substituted alkyl moieties, wherein said compound exhibits substantial biological activity in the presence of a receptor having affinity for VIP-based peptides.
Type:
Grant
Filed:
April 2, 1999
Date of Patent:
November 23, 2004
Assignee:
PerkinElmer LAS, Inc.
Inventors:
Clarissa Desjardins, Jacek Slon-Usakievicz, Alain Beaudet
Abstract: Light emitting compounds of the formula:
wherein R1 is a light-emitting moiety and R2 is a substance P-based peptide, fragment, derivative or analog thereof, said peptide being linked at an amino acid position to (C—X), wherein (C—X) is selected from the group consisting of C═O, C═S, CH(OH), C═C═O, C═NH, CH2, CH(OR), CH(NR), CH(R), CR3R4, and C(OR3)OR4 where R, R3, and R4 are alkyl moieties or substituted alkyl moieties, wherein said compound exhibits substantial biological activity in the presence of a receptor having affinity for substance P-based peptides.
Type:
Grant
Filed:
April 2, 1999
Date of Patent:
November 9, 2004
Assignee:
PerkinElmer LAS, Inc.
Inventors:
Clarissa Desjardins, Jacek Slon-Usakievicz, Alain Beaudet
Abstract: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected.
Abstract: The invention relates to a drinkable ibuprofen solution wherein the soluble fraction of the active ingredient contained therein is less than 10% by weight in relation to the weight of the suspension.
Type:
Grant
Filed:
November 6, 2001
Date of Patent:
September 21, 2004
Assignee:
Laboratoire des Produits Ethiques Ethypharm
Abstract: In one aspect, the invention relates to a method of treating infectious bursal disease (IBD) in an avian subject in need of such treatment. The method comprises administering to the subject a compound of the formulas (I) through (IV) or a pharmaceutically acceptable salt thereof in an amount sufficient to treat IBD. In another aspect, the invention relates to a method of producing active immunity against infectious bursal virus disease (IBD) in an avian subject. The method comprises administering to a subject an immunogenic-amount of an IBDV vaccine and a compound selected from the compounds of formulas (I) through (IV) described herein. The compound represented by formulas (I) through (IV) is administered in an amount sufficient to induce an immune response in the avian subject.
Type:
Grant
Filed:
November 1, 2000
Date of Patent:
August 10, 2004
Assignees:
The University of North Carolina at Chapel Hill, Georgia State University Research Foundation, Inc., Auburn University
Inventors:
Christine C. Dykstra, James C. Hudson, Sandra Ewald, Richard R. Tidwell, David W. Boykin
Abstract: Method is described for sequencing polypeptides by forming peptide ladders comprising a series of polypeptides in which adjacent members of the series vary by one amino acid residue and determining the identity and position of each amino acid in the polypeptide by mass spectroscopy.
Type:
Grant
Filed:
April 5, 2001
Date of Patent:
June 15, 2004
Assignees:
The Rockefeller University, The Scripps Research Institute
Inventors:
Brian T. Chait, Ronald Beavis, Rong Wang, Stephen B. H. Kent
Abstract: Provided are compounds of the formula (1):
wherein
R′ is hydrogen, methyl or NH2C(O)CH2—;
R″ and R′″ are independently methyl or hydrogen;
R adn Ry are independently hydroxy or hydrogen;
R1 is hydroxy, hydrogen, or hydroxysulfonyloxy;
R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy;
R2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.
Type:
Grant
Filed:
February 27, 2002
Date of Patent:
June 1, 2004
Assignee:
Eli Lilly and Company
Inventors:
Frederick J. Burkhardt, Manuel Debono, Jeffrey S. Nissen, William W. Turner, Jr.
Abstract: A composition, preferably used to reduce methane formation in a ruminant, wherein the composition is a combination of a polycyclic quinone compound and an ionophore compound.
Abstract: A method is described relating to the field of cardiovascular disease and in particular the prevention and treatment of poor cardiac function following surgery. An optimum dose of dichloracetate is described, permitting the continuous maintenance of blood therapeutic levels.
Type:
Grant
Filed:
January 18, 2002
Date of Patent:
April 27, 2004
Assignee:
University of Alberta
Inventors:
Gary Lopaschuk, Ruth Collins-Nakai, Koon Teo, Jason R. B. Dyck
Abstract: The present invention provides a percutaneously administrable preparation comprising either an aqueous base comprising 1-menthol, a lower alcohol and an acidic buffer or water, or an oily base comprising 1-menthol, a lower alcohol and isopropyl myristate, and a cerebral function activator, for example, 2-(3-isoxazolyl)-3,6,7,9-tetrahydroimidazo[4,5-d]pyrano[4,3-b]pyridine, pharmaceutically acceptable salt or hydrate thereof.
Abstract: A method for killing infectious microbial cells by exposing the microbial cells to endogenous antimicrobial compounds. Activation of the antimicrobials is achieved by addition of low permeability, non-ionic osmolytes to lower ionic strength in body fluids where the antimicrobials have been previously suppressed by alteration of ionic transport (increase in salt concentration). The method can be used to treat cystic fibrosis. Cystic fibrosis causes elevated salt concentrations in the airway surface liquid (ASL) occur due to the impaired chloride transport across the epithelia. Xylitol has been found to be an effective low permeability, non-ionic osmolyte for use in the present invention.
Abstract: Disclosed herein is a method for the treatment of otitis media and paranasal sinusitis using human defensins, lysozyme and/or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was observed that certain innate immune modulators were important in the bodies response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin and defensins, were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis.
Type:
Grant
Filed:
November 27, 2001
Date of Patent:
April 6, 2004
Assignee:
House Ear Institute
Inventors:
David J. Lim, Haa-Yung Lee, Paul Webster, Ali Andalibi, Jian-Dong Li, Tomas Ganz
Abstract: By amylase treatment of water-soluble polysaccharide aqueous solutions extracted from legumes under acidic conditions, for hydrolysis of the starch substances that are a source of precipitates and suspended matter, it is possible to improve the clarity of the aqueous solutions while also preventing production of precipitates during long-term storage or cold storage of the aqueous solutions.